115 related articles for article (PubMed ID: 32659024)
1. Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities.
Dee EC; Nezolosky MD; Chipidza FE; Arega MA; Butler SS; Sha ST; Mahal BA; Nguyen PL; Yang DD; Muralidhar V
Prostate; 2020 Sep; 80(13):1128-1133. PubMed ID: 32659024
[TBL] [Abstract][Full Text] [Related]
2. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853
[TBL] [Abstract][Full Text] [Related]
3. Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer.
Xiang M; Nguyen PL
Brachytherapy; 2015; 14(6):773-80. PubMed ID: 26489921
[TBL] [Abstract][Full Text] [Related]
4. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
5. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
[TBL] [Abstract][Full Text] [Related]
6. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
7. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
[TBL] [Abstract][Full Text] [Related]
8. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
9. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
Muralidhar V; Chen MH; Reznor G; Moran BJ; Braccioforte MH; Beard CJ; Feng FY; Hoffman KE; Choueiri TK; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):828-35. PubMed ID: 26530751
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
11. Commentary on "initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer." Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Harvard Radiation Oncology program, Boston, MA.: BJU Int 2013. doi: 10.1111/j.1464-410X.2012.11789.x. [Epub ahead of print].
Ritter MA
Urol Oncol; 2014 Feb; 32(2):208-9. PubMed ID: 24445289
[TBL] [Abstract][Full Text] [Related]
12. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
Mahal BA; Muralidhar V; Chen YW; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Trinh QD; Nguyen PL
BJU Int; 2016 Jul; 118(1):95-101. PubMed ID: 26207642
[TBL] [Abstract][Full Text] [Related]
13. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
14. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
Nguyen PL; Chen MH; Catalona WJ; Moul JW; Sun L; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):659-64. PubMed ID: 18692327
[TBL] [Abstract][Full Text] [Related]
15. How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
He H; Han D; Xu F; Lyu J
Prostate; 2022 Mar; 82(4):415-424. PubMed ID: 34927741
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database.
Shukla ME; Yu C; Reddy CA; Stephans KL; Klein EA; Abdel-Wahab M; Ciezki J; Tendulkar RD
Clin Genitourin Cancer; 2015 Feb; 13(1):17-21. PubMed ID: 25571871
[TBL] [Abstract][Full Text] [Related]
17. Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.
Ashamalla H; Guirguis A; McCool K; McVorran S; Mattes M; Metzger D; Oromendia C; Ballman KV; Mokhtar B; Tchelebi M; Katsoulakis E; Rafla S
Brachytherapy; 2017; 16(2):323-329. PubMed ID: 28139417
[TBL] [Abstract][Full Text] [Related]
18. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Loffredo MJ; Kantoff PW; Renshaw AA; D'Amico AV
Cancer; 2014 Jun; 120(12):1787-93. PubMed ID: 24604289
[TBL] [Abstract][Full Text] [Related]
19. Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis.
Muralidhar V; Mahal BA; Nguyen PL
Radiat Oncol; 2015 Jul; 10():155. PubMed ID: 26220664
[TBL] [Abstract][Full Text] [Related]
20. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Brachytherapy; 2015; 14(6):781-7. PubMed ID: 26361718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
